Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
15.33
-1.90 (-11.03%)
At close: Nov 20, 2024, 4:00 PM
15.05
-0.28 (-1.83%)
After-hours: Nov 20, 2024, 7:59 PM EST

Neurogene Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Cost of Revenue
57.6544.3947.5142.26
Gross Profit
-56.73-44.39-47.51-42.26
Selling, General & Admin
1911.199.018.27
Operating Expenses
1911.199.018.27
Operating Income
-75.73-55.58-56.52-50.53
Interest Expense
-0.01-0.01-0-
Interest & Investment Income
6.982.951.340.02
Other Non Operating Income (Expenses)
-0.74-0.03-0.01-
EBT Excluding Unusual Items
-69.5-52.67-55.19-50.52
Other Unusual Items
16.3616.36--
Pretax Income
-53.25-36.32-55.19-50.52
Net Income
-53.25-36.32-55.19-50.52
Preferred Dividends & Other Adjustments
-49.97-49.97--
Net Income to Common
-3.2813.65-55.19-50.52
Shares Outstanding (Basic)
13004
Shares Outstanding (Diluted)
13504
Shares Change (YoY)
116.71%1080.37%-90.26%-
EPS (Basic)
-0.2527.76-139.88-12.47
EPS (Diluted)
-0.262.93-139.88-12.47
Free Cash Flow
-70.9-51.74-55.05-64.77
Free Cash Flow Per Share
-5.51-11.11-139.54-15.99
EBITDA
-72.45-52.29-53.32-49.59
D&A For EBITDA
3.283.33.20.95
EBIT
-75.73-55.58-56.52-50.53
Source: S&P Capital IQ. Standard template. Financial Sources.